BRIACELL THERAPEUTICS CORP. Research And Development Expense
BRIACELL THERAPEUTICS CORP. (BCTX) reported Research And Development Expense of $2.54 million for the 3-month period ending 2022-04-30, per its 6-K filed 2022-06-13.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2022-06-13
- BRIACELL THERAPEUTICS CORP. research and development expense for the quarter ending 2022-04-30 was $2.54M, a 126.00% increase year-over-year.
- BRIACELL THERAPEUTICS CORP. research and development expense for the quarter ending 2022-01-31 was $1.73M, a 946.88% increase year-over-year.
- BRIACELL THERAPEUTICS CORP. research and development expense for the quarter ending 2021-07-31 was -$124.58K.
- BRIACELL THERAPEUTICS CORP. research and development expense for the quarter ending 2021-04-30 was $1.13M.
| Period end | Research And Development Expense 0 month | Research And Development Expense 3 month | Research And Development Expense 6 month | Research And Development Expense 9 month | Research And Development Expense 12 month |
|---|---|---|---|---|---|
| 2022-04-30 | $2.54M 6-K · filed 2022-06-13 | $4.28M derived: sum of 2 quarters · filed 2022-06-13 | $5.15M 6-K · filed 2022-06-13 | ||
| 2022-01-31 | $1.73M 6-K · filed 2022-03-15 | $2.61M 6-K · filed 2022-03-15 | |||
| 2021-07-31 | -$124.58K derived: 40-F/A 12 month − 6-K 9 month · filed 2021-11-16 | $1.00M derived: sum of 2 quarters · filed 2022-06-13 | $1.17M derived: sum of 3 quarters · filed 2022-06-13 | $1.32M 40-F/A · filed 2021-11-16 | |
| 2021-04-30 | $1.13M 6-K · filed 2022-06-13 | $1.29M derived: sum of 2 quarters · filed 2022-06-13 | $1.44M 6-K · filed 2022-06-13 | ||
| 2021-01-31 | $165.59K 6-K · filed 2022-03-15 | $314.65K 6-K · filed 2022-03-15 | |||
| 2020-07-31 | $2.43M 40-F/A · filed 2021-11-16 | ||||
| 2019-08-01 | $4.00M 40-F/A · filed 2021-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |